Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

Date Issued
2017
Author(s)
Germing, Ulrich
Schuler, Esther
Platzbecker, Uwe
Nolte, Florian
Hofmann, Wolf-Karsten
Giagounidis, Aristoteles
Götze, Katharina
Lübbert, Michael
Schlenk, Richard F.
Ganser, Arnold
Büsche, Guntram
Letsch, Anne
Schafhausen, Philippe
Bug, Gesine
Brümmendorf, Tim H.
Haas, Rainer
DOI
10.1007/s00277-017-2983-0